Harbour BioMed Launches Elance Therapeutics for Obesity Therapies

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, announced the launch of Élancé Therapeutics (Élancé). Harnessing Harbour BioMed’s proprietary HCAb-based bispecific antibody technology, Élancé aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy.

Obesity affects nearly one billion people worldwide and is associated with serious health complications, yet current treatments remain inadequate for many patients. Despite recent advancements, challenges such as limited efficacy, lean mass loss, and post-treatment weight regain highlight the need for novel approaches that offer sustained benefits and better clinical outcome.

To address these gaps, Élancé is building a pipeline of bispecific antibody programs designed to improve weight loss outcomes while preserving lean muscle mass. By integrating dual-targeting strategies with enhanced safety profiles, these therapies have the potential to complement and expand upon existing treatment options, including various agonists of GLP-1 receptor, GIP receptor, and GCG receptor.

Élancé’s pipeline includes multiple bispecific antibody programs in preclinical development, each designed to offer innovative mechanisms of action, including targeted hormone modulation and enhanced metabolic regulation. These programs are supported by Harbour BioMed’s validated HCAb-based bispecific antibody discovery platform, which has been successfully applied across multiple therapeutic areas. In addition, Élancé will refine and expand Nona Biosciences’ Hu-mAtrIx AI platform to support bispecific antibody discovery, with AI applications guiding antibody sequence discovery, enrichment, optimization, bispecific geometry design, and developability/immunogenicity/pharmacokinetics (PK) assessments, as well as patient biomarker studies.

“Our bispecific antibody programs enable a new paradigm in obesity treatment by targeting multiple pathways in a precise and effective manner,” said Jingsong Wang, MD, PhD, founder, chairman, and CEO of Harbour BioMed. “With a focus on optimizing weight loss efficacy, preserving lean muscle mass, and improving long-term outcomes, we believe our approach has the potential to redefine obesity therapeutics.”

Harbour BioMed is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology.

Élancé Therapeutics is a biotechnology company developing next-generation biologics for obesity treatment. Incubated by Harbour BioMed, Élancé Therapeutics leverages advanced bispecific antibody technology to address key challenges in obesity management, including limited efficacy, lean mass loss, and post-treatment weight regain.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!